Evidence map›Paper›PMID 36179551›Full record

SynthesisEBioMedicine2022

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.

Yunda Huang, Yuanyuan Zhang, Kelly E Seaton, Stephen De Rosa, Jack Heptinstall, Lindsay N Carpp, April Kaur Randhawa, Lyle R McKinnon, Paul McLaren, Edna Viegas and 15 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 4 countries.

Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America; Department of Global Health, University of Washington, Seattle, WA, United States of America. Electronic address: yunda@scharp.org.
Yuanyuan ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
Kelly E SeatonCenter for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.
Stephen De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
Jack HeptinstallCenter for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.
Lindsay N CarppVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
April Kaur RandhawaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
Lyle R McKinnonDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MN, Canada; JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MN, Canada; Centre for the AIDS Program of Research in South Africa (CAPRISA), Durban, South Africa.
Paul McLarenDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MN, Canada; JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MN, Canada.
Edna ViegasInstituto Nacional de Saúde, Maputo, Mozambique.
Glenda E GrayPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa.
Gavin ChurchyardAurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa.
Susan P BuchbinderBridge HIV, San Francisco Department of Public Health, San Francisco, CA, United States of America; Department of Medicine and Department of Epidemiology, University of California, San Francisco, CA, United States of America.
Srilatha EdupugantiDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Michael C KeeferDepartment of Medicine, Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America.
Mina C HosseinipourUniversity of North Carolina Project, Lilongwe, Malawi; Department of Medicine, Institution for Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.
Paul A GoepfertDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Kristen W CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
Brian D WilliamsonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America; Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of America.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
Georgia D TomarasCenter for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.
Juilee ThakarDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States of America.
James J KobieDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: jjkobie@uabmc.edu.
NIAID HIV Vaccine Trials Network (HVTN) 073/South African AIDS Vaccine Initiative (SAAVI) 102, HVTN 086/SAAVI 103, HVTN 094, HVTN 097, HVTN 098, HVTN 100, HVTN 105, HVTN 111, and HVTN 205 Protocol Leadership Teams
Fred Hutch Cancer Center · USDuke University · USPublic Health Agency of Canada · CAUniversity of Alabama at Birmingham · USUniversity of Rochester · USDesmond Tutu HIV Foundation · ZAEmory University · USInfectious Disease Research Institute · USInstituto Nacional de Saúde · MZSouth African Medical Research Council · ZAUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USUniversity of the Witwatersrand · ZAUniversity of Washington · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
University of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7M
Seattle Vaccine Trials UnitUM1AI069481 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Rachel Ann Bender Ignacio, Margaret Juliana McElrath · 2012 to 2026
$24.4M
Aurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1M
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIVR01DE027245 · NIDCR · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2017 to 2021
$3.7M
Targeting IgM Memory to Establish Protective B Cell Responses to HIVR01AI117787 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2018
$2.7M
NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI117787NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069481NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI154463NIDCR NIH HHS R01 DE027245
6 · The paper itself

Abstract

backgroundThe identification of baseline host determinants that associate with robust HIV-1 vaccine-induced immune responses could aid HIV-1 vaccine development. We aimed to assess both the collective and relative performance of baseline characteristics in classifying individual participants in nine different Phase 1-2 HIV-1 vaccine clinical trials (26 vaccine regimens, conducted in Africa and in the Americas) as High HIV-1 vaccine responders.

methodsThis was a meta-analysis of individual participant data, with studies chosen based on participant-level (vs. study-level summary) data availability within the HIV-1 Vaccine Trials Network. We assessed the performance of 25 baseline characteristics (demographics, safety haematological measurements, vital signs, assay background measurements) and estimated the relative importance of each characteristic in classifying 831 participants as High (defined as within the top 25th percentile among positive responders or above the assay upper limit of quantification) versus Non-High responders. Immune response outcomes included HIV-1-specific serum IgG binding antibodies and Env-specific CD4+ T-cell responses assessed two weeks post-last dose, all measured at central HVTN laboratories. Three variable importance approaches based on SuperLearner ensemble machine learning were considered.

findingsOverall, 30.1%, 50.5%, 36.2%, and 13.9% of participants were categorized as High responders for gp120 IgG, gp140 IgG, gp41 IgG, and Env-specific CD4+ T-cell vaccine-induced responses, respectively. When including all baseline characteristics, moderate performance was achieved for the classification of High responder status for the binding antibody responses, with cross-validated areas under the ROC curve (CV-AUC) of 0.72 (95% CI: 0.68, 0.76) for gp120 IgG, 0.73 (0.69, 0.76) for gp140 IgG, and 0.67 (95% CI: 0.63, 0.72) for gp41 IgG. In contrast, the collection of all baseline characteristics yielded little improvement over chance for predicting High Env-specific CD4+ T-cell responses [CV-AUC: 0.53 (0.48, 0.58)]. While estimated variable importance patterns differed across the three approaches, female sex assigned at birth, lower height, and higher total white blood cell count emerged as significant predictors of High responder status across multiple immune response outcomes using Approach 1. Of these three baseline variables, total white blood cell count ranked highly across all three approaches for predicting vaccine-induced gp41 and gp140 High responder status.

interpretationThe identified features should be studied further in pursuit of intervention strategies to improve vaccine responses and may be adjusted for in analyses of immune response data to enhance statistical power.

fundingNational Institute of Allergy and Infectious Diseases (UM1AI068635 to YH, UM1AI068614 to GDT, UM1AI068618 to MJM, and UM1 AI069511 to MCK), the Duke CFAR P30 AI064518 to GDT, and National Institute of Dental and Craniofacial Research (R01DE027245 to JJK). This work was also supported by the Bill and Melinda Gates Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding sources.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsHIV SeropositivityAdultAntibody FormationFemaleHIV AntibodiesHumansImmunoglobulin GMaleAIDS VaccinesHIV AntibodiesImmunoglobulin GAntibodyBaseline characteristicsCD4+ T cellSuperLearnerVaccine response heterogeneityVariable importance measurements

Identifiers

PMID36179551
PMCPMC9520208
OpenAlexW4297364309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.